Which has better earnings and valuation, OXB or GNS?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oxford Biomedica £168.74M 3.43 -£143.51M -£26.92 N/A Genus £672M 2.28 £7.87M £71.00 32.56

Is OXB or GNS more profitable?

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Oxford Biomedica -17.85% -48.56% -12.67% Genus 7.07% 9.70% 3.31%

Do analysts prefer OXB or ERGO?

Oxford Biomedica presently has a consensus price target of GBX 669.85, suggesting a potential upside of 40.06%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts plainly believe Oxford Biomedica is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is OXB or ERGO more profitable?

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Oxford Biomedica -17.85% -48.56% -12.67% Ergomed 9.87% 18.08% 10.16%

Do analysts recommend OXB or SLN?

Oxford Biomedica currently has a consensus target price of GBX 669.85, suggesting a potential upside of 40.06%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities research analysts plainly believe Oxford Biomedica is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Oxford Biomedica (OXB) Competitors

GBX 478.25 -112.75 (-19.08%)

As of 07:37 AM Eastern

Compare

OXB vs. GNS, ONT, ERGO, SLN, and AVCT

Should you buy Oxford Biomedica stock or one of its competitors? MarketBeat compares Oxford Biomedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford Biomedica include Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.

How does Oxford Biomedica compare to Genus?

Oxford Biomedica (LON:OXB) and Genus (LON:GNS) are related small-cap companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Genus	7.07%	9.70%	3.31%

Oxford Biomedica has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Genus has a beta of 0.901, meaning that its share price is 10% less volatile than the broader market.

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A
Genus	£672M	2.28	£7.87M	£71.00	32.56

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 51.9% of Genus shares are held by institutional investors. 25.8% of Oxford Biomedica shares are held by insiders. Comparatively, 0.7% of Genus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oxford Biomedica presently has a consensus price target of GBX 669.85, suggesting a potential upside of 40.06%. Genus has a consensus price target of GBX 3,216.67, suggesting a potential upside of 39.13%. Given Oxford Biomedica's higher probable upside, research analysts plainly believe Oxford Biomedica is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Genus had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 1 mentions for Genus and 0 mentions for Oxford Biomedica. Genus' average media sentiment score of 0.55 beat Oxford Biomedica's score of 0.00 indicating that Genus is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Genus	Positive

Summary

Genus beats Oxford Biomedica on 10 of the 15 factors compared between the two stocks.

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Oxford Biomedica (LON:OXB) and Oxford Nanopore Technologies (LON:ONT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 16.4% of Oxford Nanopore Technologies shares are owned by institutional investors. 25.8% of Oxford Biomedica shares are owned by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oxford Biomedica has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A
Oxford Nanopore Technologies	£223.90M	5.30	-£175.21M	-£15.10	N/A

In the previous week, Oxford Nanopore Technologies had 2 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Oxford Nanopore Technologies and 0 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 0.75 beat Oxford Biomedica's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Oxford Nanopore Technologies	Positive

Oxford Biomedica has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Oxford Biomedica currently has a consensus price target of GBX 669.85, suggesting a potential upside of 40.06%. Oxford Nanopore Technologies has a consensus price target of GBX 205.75, suggesting a potential upside of 69.06%. Given Oxford Nanopore Technologies' higher possible upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Oxford Biomedica and Oxford Nanopore Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Ergomed?

Oxford Biomedica (LON:OXB) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Oxford Biomedica's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Ergomed	Neutral

Ergomed has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Oxford Biomedica has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Ergomed	9.87%	18.08%	10.16%

Oxford Biomedica presently has a consensus price target of GBX 669.85, suggesting a potential upside of 40.06%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts plainly believe Oxford Biomedica is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 25.8% of Oxford Biomedica shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Ergomed beats Oxford Biomedica on 7 of the 13 factors compared between the two stocks.

How does Oxford Biomedica compare to Silence Therapeutics?

Oxford Biomedica (LON:OXB) and Silence Therapeutics (LON:SLN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

32.4% of Oxford Biomedica shares are owned by institutional investors. 25.8% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Oxford Biomedica's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Silence Therapeutics	Neutral

Silence Therapeutics has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

Silence Therapeutics has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Silence Therapeutics	N/A	N/A	N/A

Oxford Biomedica currently has a consensus target price of GBX 669.85, suggesting a potential upside of 40.06%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities research analysts plainly believe Oxford Biomedica is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Oxford Biomedica beats Silence Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Oxford Biomedica compare to Avacta Group?

Oxford Biomedica (LON:OXB) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Oxford Biomedica has a net margin of -17.85% compared to Avacta Group's net margin of -33,961.06%. Oxford Biomedica's return on equity of -48.56% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Oxford Biomedica has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Avacta Group has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A
Avacta Group	£113K	2,784.46	-£30.08M	-£9.66	N/A

In the previous week, Avacta Group had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Oxford Biomedica. Avacta Group's average media sentiment score of 0.67 beat Oxford Biomedica's score of 0.00 indicating that Avacta Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Avacta Group	Positive

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 3.1% of Avacta Group shares are owned by institutional investors. 25.8% of Oxford Biomedica shares are owned by company insiders. Comparatively, 47.7% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Oxford Biomedica currently has a consensus target price of GBX 669.85, indicating a potential upside of 40.06%. Avacta Group has a consensus target price of GBX 99, indicating a potential upside of 47.42%. Given Avacta Group's higher possible upside, analysts clearly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Avacta Group beats Oxford Biomedica on 8 of the 14 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OXB vs. The Competition

Export

Metric	Oxford Biomedica	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£578.86M	£3.61B	£6.95B	£2.88B
Dividend Yield	4.57%	3.76%	2.59%	6.11%
P/E Ratio	-17.77	8.36	271.22	368.41
Price / Sales	3.43	1,279.23	657.29	83,671.57
Price / Cash	3.01	101.37	71.89	27.89
Price / Book	7.06	17.66	13.03	7.14
Net Income	-£143.51M	-£13.22M	£3.46B	£5.89B
7 Day Performance	-14.60%	4.42%	3.40%	1.82%
1 Month Performance	-20.02%	-4.91%	-2.68%	1.48%
1 Year Performance	8.42%	56.59%	76.00%	74.46%

Oxford Biomedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OXB Oxford Biomedica	N/A	GBX 478.25 -19.1%	GBX 669.85 +40.1%	+28.6%	£578.86M	£168.74M	N/A	891	Gap Up High Trading Volume
GNS Genus	3.6979 of 5 stars	GBX 2,244 +0.8%	GBX 3,216.67 +43.3%	-7.3%	£1.49B	£672M	31.61	480	Gap Up
ONT Oxford Nanopore Technologies	3.6228 of 5 stars	GBX 113.90 +1.3%	GBX 212.60 +86.7%	-45.0%	£1.11B	£223.90M	N/A	1,281
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OXB) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Biomedica (OXB) Competitors

OXB vs. GNS, ONT, ERGO, SLN, and AVCT

How does Oxford Biomedica compare to Genus?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Summary

How does Oxford Biomedica compare to Ergomed?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Summary

How does Oxford Biomedica compare to Avacta Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Biomedica (OXB) Competitors

OXB vs. GNS, ONT, ERGO, SLN, and AVCT

How does Oxford Biomedica compare to Genus?

Is OXB or GNS more profitable?

Which has more risk and volatility, OXB or GNS?

Which has better earnings and valuation, OXB or GNS?

Do institutionals & insiders have more ownership in OXB or GNS?

Do analysts prefer OXB or GNS?

Does the media favor OXB or GNS?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Do institutionals and insiders hold more shares of OXB or ONT?

Which has better valuation & earnings, OXB or ONT?

Does the media prefer OXB or ONT?

Which has more risk & volatility, OXB or ONT?

Is OXB or ONT more profitable?

Do analysts prefer OXB or ONT?

Summary

How does Oxford Biomedica compare to Ergomed?

Does the media prefer OXB or ERGO?

Which has better valuation and earnings, OXB or ERGO?

Which has more volatility and risk, OXB or ERGO?

Is OXB or ERGO more profitable?

Do analysts prefer OXB or ERGO?

Do institutionals & insiders hold more shares of OXB or ERGO?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Do insiders & institutionals hold more shares of OXB or SLN?

Does the media prefer OXB or SLN?

Which has stronger earnings & valuation, OXB or SLN?

Is OXB or SLN more profitable?

Do analysts recommend OXB or SLN?

Summary

How does Oxford Biomedica compare to Avacta Group?

Is OXB or AVCT more profitable?

Which has more risk & volatility, OXB or AVCT?

Which has preferable earnings & valuation, OXB or AVCT?

Does the media prefer OXB or AVCT?

Do insiders and institutionals believe in OXB or AVCT?

Do analysts rate OXB or AVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools